Q: What is the intention of Bayer Schering Pharma to make a major investment in Glucobay with ACE?

    Q: 拜耳先灵医药大力投资ACE研究的目的是什么？

    A: Glucobay  is a well established effective oral treatment with an excellent safety profile conveniently taken at mealtimes. In the markets where it is approved， it is a major and recognized treatment for improving prediabetes， diabetes and related cardiovascular risk management.
    Bayer Schering Pharma considers it as its duty to contribute to the worldwide fight against the diabetes epidemic and is dedicated to advancing research and generating clinically-meaningful results. This has been demonstrated with the landmark trial STOP-NIDDM and now， ACE， which again demonstrates a major investment in diabetes and a next logical step to expanding evidence for Glucobay?? in patients with established CVD and elevated blood glucose levels， to help decrease the global burden imposed by the diabetes epidemic: We take Diabetes to Heart!

    A: 拜唐苹这一口服降糖药物的良好安全性已经得到广泛验证，而且其餐时服用的给药方式非常方便。在获得批准的国家，拜唐苹是值得信赖的能够改善糖尿病前期、糖尿病及其相关心血管风险的主要治疗药物。
    目前在全球范围内都进行着迎战糖尿病流行的斗争，拜耳先灵医药以参与这一斗争为己任，专注于前沿研究并取得了具有临床价值的成果，如开展具有里程碑意义的STOP-NIDDM以及目前的ACE研究。ACE研究是又一项关于糖尿病及其并发症的主要投资，我们期待它能在合并CVD的糖尿病前期患者中延伸拜唐苹治疗的证据链，从而降低糖尿病流行造成的全球负担——将血糖管理深入人心!